Brief: Aelis Farma Says AEF0217 Well Tolerated With No Safety Concerns Identified
18/11/2024 18:45
Nov 18 (Reuters) - Aelis Farma SA AELIS.PA :
* ANNOUNCES THE POSITIVE RESULTS OF ITS CLINICAL PHASE 1/2
STUDY
WITH AEF0217 IN YOUNG ADULTS WITH DOWN SYNDROME
* AEF0217 WELL TOLERATED WITH NO SAFETY CONCERNS IDENTIFIED
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Aelis Farma SA
See all newsBrief: Aelis Farma Availability Of 2025 Half-Year Financial Report
Brief: Euronext: Quarterly Review Of CAC Family
Brief: Aelis Farma Confirms Its 2025 Outlook
Brief: Aelis Farma Announces The Final Analysis Of Phase 2B Clinical Trial In Cannabis Use Disorder With AEF0117
Brief: Aelis Farma Says AEF0217 Well Tolerated With No Safety Concerns Identified